Preclinical News and Research

RSS

University of Nottingham research developments could mean new drugs will reach cancer patients more quickly

A £3 million grant and the establishment of a specialized business unit that will help new treatments reach cancer patients more quickly, have underlined The University of Nottingham’s place at the forefront of cancer drug development.

2 Sep 2004

New drug application for exenatide has been accepted for review

Amylin Pharmaceuticals and Eli Lilly today announced that the New Drug Application for exenatide has been accepted for review by the Food and Drug Administration.

2 Sep 2004

Interim data from human clinical trials of two AIDS vaccine candidates, named DNA.HIVA and MVA.HIVA

The interim data, from 205 volunteers in clinical trials in Kenya, Uganda and the United Kingdom, show that DNA.HIVA and MVA.HIVA are generally safe and well tolerated. However, the candidates’ ability to elicit an anti-HIV cell-mediated immune response is poor, using currently accepted measures of immune response.

30 Aug 2004

Kiwis reverse heart disease in diabetics

New Zealand biopharmaceutical company Protemix Corporation has announced the discovery of a treatment which appears to reverse heart disease in people suffering from diabetes and may lead to a more effective intervention in a major cause of death worldwide.

30 Aug 2004

New study confirms benefits of rimonabant in weight loss

Phase III clinical study comparing placebo to rimonabant, the first agent in a new therapeutic class known as selective cannabinoid type 1 (CB1) blockers, showed that overweight or obese people taking rimonabant 20mg once daily benefited from a significant reduction in their body weight

29 Aug 2004

Phase 1 clinical trial of new anticancer drug from Human Genome Sciences

Human Genome Sciences has begun dosing patients in a Phase 1 clinical trial of HGS-TR2J, a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.

25 Aug 2004

Dual-action compound shows promise in killing prostate cancer cells

Ohio State University researchers are working on developing a multi-purpose cancer drug that might one day scale back the number of medications some cancer patients need to take.

22 Aug 2004

Corkscrew-like device that removes blood clots from the brains of stroke sufferers

The device "appears fairly safe and has the potential to make dramatic differences in stroke therapy," said Wayne Clark, M.D., professor of neurology and director of the Oregon Stroke Center.

18 Aug 2004

Study on RNAi technology targeting neurodegenerative diseases

Sirna Therapeutics has announced the publication of preclinical studies evaluating RNA interference-based therapies for a class of inherited neurodegenerative diseases of the central nervous system (CNS) in the current issue of Nature Medicine.

16 Aug 2004

No adverse side-effects have been observed in clinical trial of SARS vaccine

Sinovac Biotech has announced that all 36 subjects of the Phase I human clinical trial for its inactivated SARS vaccine have now been vaccinated with either SARS vaccine or placebo.

11 Aug 2004

Clinical trial of lipase inhibitor for the treatment of obesity

Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability and pharmacokinetics of GT389-255, a lipase inhibitor conjugated to a fat binding polymer for the treatment of obesity.

9 Aug 2004

Second case of variant Creutzfeldt-Jakob disease infection that was probably caused by blood transfusion

Research reported in The Lancet this week details the second case of variant Creutzfeldt-Jakob disease (vCJD) infection that was probably caused by blood transfusion. The rogue prion responsible for vCJD was identified at postmortem five years after an elderly person received a blood transfusion from a donor who later developed vCJD.

5 Aug 2004

Promising new cancer drug, Nanotax

A Lawrence company that uses patented technology created at the University of Kansas to improve the effectiveness of drugs has won a $100,000 National Institutes of Health grant to support further testing of the company's promising new cancer drug, Nanotax.

5 Aug 2004

Rheumatoid arthritis and early indicators of disease

A chronic autoimmune disease marked by severe inflammation and joint, rheumatoid arthritis (RA) is a major cause of pain and disability.

5 Aug 2004

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

Metabasis Therapeutics has announced the initiation of a multi-center, multi- national Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate in chronic hepatitis B (HBV) infected patients.

3 Aug 2004

Miniature spectroscopic instruments and software to look at changes that occur within the cells and tissue of the brain

When molecules in cells are stimulated by light, they respond by becoming excited and re-emitting light of varying colors (fluorescence) that can be captured and measured by highly sensitive optical equipment.

2 Aug 2004

Research collaboration to discover novel oral drugs for the treatment of viral infections

Sunesis Pharmaceuticals, Inc. and Merck & Co., Inc. have announced that they have entered into a multi-year research collaboration to discover novel oral drugs for the treatment of viral infections.

29 Jul 2004

Transplanted cells are capable of surviving in the brain of immunosuppressed stroked rats

Human neural stem cells proprietary to StemCells, Inc. have been used in a Stanford University study in a preclinical stroke model.

29 Jul 2004

Australian collaboration to produce cancer immunotherapy vaccines

A Brisbane based biomedical company, Tissue Therapies Limited (TIS) and the Queensland Institute of Medical Research (QIMR) have agreed on the terms of a new collaboration aimed at developing Tissue Therapies' VitroGro® cell growth technology as a platform to produce cancer immunotherapy vaccines.

21 Jul 2004

Radiance FN/Radiesse injectable implant material appears effective and well tolerated by patients undergoing facial soft tissue augmentation

An article in the July/August issue of the Archives of Facial Plastic Surgery reports that the use of Radiance FN/Radiesse injectable implant material appears effective and well tolerated by patients undergoing facial soft tissue augmentation, and patient satisfaction with treatment is high.

20 Jul 2004

Preclinical News and Research

University of Nottingham research developments could mean new drugs will reach cancer patients more quickly

New drug application for exenatide has been accepted for review

Interim data from human clinical trials of two AIDS vaccine candidates, named DNA.HIVA and MVA.HIVA

Kiwis reverse heart disease in diabetics

New study confirms benefits of rimonabant in weight loss

Phase 1 clinical trial of new anticancer drug from Human Genome Sciences

Dual-action compound shows promise in killing prostate cancer cells

Corkscrew-like device that removes blood clots from the brains of stroke sufferers

Study on RNAi technology targeting neurodegenerative diseases

No adverse side-effects have been observed in clinical trial of SARS vaccine

Clinical trial of lipase inhibitor for the treatment of obesity

Second case of variant Creutzfeldt-Jakob disease infection that was probably caused by blood transfusion

Promising new cancer drug, Nanotax

Rheumatoid arthritis and early indicators of disease

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

Miniature spectroscopic instruments and software to look at changes that occur within the cells and tissue of the brain

Research collaboration to discover novel oral drugs for the treatment of viral infections

Transplanted cells are capable of surviving in the brain of immunosuppressed stroked rats

Australian collaboration to produce cancer immunotherapy vaccines

Radiance FN/Radiesse injectable implant material appears effective and well tolerated by patients undergoing facial soft tissue augmentation

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News